1610761-46-0
1610761-46-0
Chemical Structure
Plozalizumab
Synonym(s): MLN-1202
- CAS No.: 1610761-46-0
- Formula:N/A
- Molecular Weight:(146.08 kDa)
SMILES: [Plozalizumab]
Biological Activity: Plozalizumab (MLN-1202) is a humanized anti-CCR2 IgG1 monoclonal antibody. Plozalizumab blocks the recruitment of myeloid cells to the tumor microenvironment by inhibiting the CCL2/CCR2 axis. In addition, Plozalizumab also ameliorates synovial inflammation in rheumatoid arthritis. Plozalizumab can be used in the research of malignant melanoma and bone metastasis-related cancers. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001)[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Plozalizumab | 99.53% | Plozalizumab (MLN-1202) is a humanized anti-CCR2 IgG1 monoclonal antibody. Plozalizumab blocks the recruitment of myeloid cells to the tumor microenvironment by inhibiting the CCL2/CCR2 axis. In addition, Plozalizumab also ameliorates synovial inflammation in rheumatoid arthritis. Plozalizumab can be used in the research of malignant melanoma and bone metastasis-related cancers. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Piehl F, et al. Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis. J Intern Med. 2021;289(6):771-791. [Content Brief]
- [2]. Jahchan NS, et al. Tuning the Tumor Myeloid Microenvironment to Fight Cancer. Front Immunol. 2019;10:1611. Published 2019 Jul 25. [Content Brief]
- [3]. Majety M, et al. A drug development perspective on targeting tumor-associated myeloid cells. FEBS J. 2018;285(4):763-776. [Content Brief]
